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1. Introduction
Cancer is the leading cause of death in economically developed countries and the second
leading cause of death in developing countries (WHO)1. It is extraordinarily complex with
novel mutations and phenotypes that are often unique to an individual. It is a disease of
the chromosomes and the problem is, in almost all cancers, it isn't just one mutation but
may be much more. Cancer may be regarded as a complex metabolic deficiency disease [9,
10, 11, 12, 13, 14]
Cancer diet is also used as a complementary approach to cancer that involves the use of special
nutritional supplements. Selenium (Se) and cancer is a term that can be referred to the approach
or associations between cancer and nutrition that is to lower an individual’s risk of cancer.
Selenium was first recognized as having some nutritional importance almost six decades ago
[15]. Selenium is found in food as selenoamino acids or selenoproteins, and as selenide,
selenite, or selenate [16]. Selenium is a critical cofactor in the activity of gluthathione peroxidase
and is also important in the management of peroxynitrite. The selenium content of food
depends upon soil content and varies regionally and nationally, with soil levels relatively low
in most European countries [17, 18, 19]. Soil conditions have been associated with clinical
selenium toxicity in animals (selenosis) in some areas with very high selenium content, and
with selenium deficiency syndromes in animals and humans in areas of low soil selenium [17].
Selenium is essential nutrient that act as cofactor in enzyme oxidation–reduction reactions (e.g.
iodothyronine deiodinase and glutathione peroxidases) [20]. It maintains the specific config‐
uration of proteins, is incorporated into the structure of hormones, and plays a structural and
catalytic role in gene expression and transcriptional regulation. The trace element selenium is
contained in soil and drinking water varies from area to area, which determines the variation
in intake seen in different communities and the amount and chemistry of dietary constituents
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eaten with the this element affect the absorption efficiency of the selenium is said be ‘the only
trace element to be specified in the genetic code’ [21].
Selenocysteine is a vital component of 35 or more selenoproteins, some of which are important
enzymes [22]. Selenium functions as a redox centre, an example of which is the reduction of
hydrogen peroxide and lipid and phospholipid hydroperoxides to nondamaging water and
alcohols by the glutathione peroxidases [23]. Functions of this kind help maintain membrane
integrity, and protect prostacyclin production. Prevention of the oxidative chain reactions in
this way prevents further damage to lipids, lipoproteins, and DNA; hence its antioxidant
function helps prevent atheroma and cancer, among other things [24, 25, 26].
2. Clinical applications
Selenium deficiency results in impaired immunity [27], and supplementation is immune
stimulant. Deficiency increases the virulence of some viruses such as in Keshan disease [28,
29] by altering their genome to a more virulent one. Deficiency may also be associated with
low mood [30], increased cognitive decline in older people, and susceptibility to epilepsy [31],
exacerbates hypothyroidism in iodine deficiency [32], protective against cardiovascular
disease and cancer [33, 34], beneficial in a variety of inflammatory conditions by reducing
oxidative stress, and in male fertility [35] through testosterone synthesis and spermatozoa
function.
The conventional cancer therapies currently available are surgery, radiotherapy, and chemo‐
therapy. Chemotherapy is typically the main regimen for most cancers. However, many
tumours develop resistance to these harsh drugs, known as chemo resistance, which can lead
to other complications [36]. A number of natural products and compounds have been shown
to act as effective chemo sensitizers. However, taking antioxidants during cancer treatment
could interfere with the way chemotherapy work and diminish their benefits to the patient
[37]. It was conclude that the use of supplemental antioxidants during chemotherapy and
radiation therapy should be discouraged because of the possibility of tumour protection and
reduced survival [37].This is because radiation and some chemotherapy agents work by
generating free radicals, which then kill rapidly dividing cancer cells. Since antioxidants
scavenge free radicals, they might interfere with the therapeutic effects of these treatments.
However, oxidation supports the proliferation of malignant cells and may itself interfere with
treatment [38]. People who hold this view maintain that antioxidants may counter the harmful
effects of oxidation in the malignant process and thereby increase the effects of drugs or
radiation therapy to the benefit of the patient. Moreover, they note that some evidence suggests
that antioxidant supplements offer patients protection from the toxic effects of therapy [39].
The balance between oxidants and antioxidants can be a key issue in the development of cancer
[40] and reactive oxygen species (ROS) are involved in aging, chronic illness, and cancer.
Oxidants also cause free radical damage, thus the body generates large amounts of antioxi‐
dants to prevent harm and maintain health. However, Watson [41] reported that antioxidants
can promote cancer growth of late stage metastatic cancers. The process is explained in terms
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of redox signalling, redox being a term used for reduction and oxidation. Healthy cells and
also malignant ones benefit from intact Keap1/Nrf2 signalling, making a dysregulated
hydroperoxide signaling a plausible explanation for the increased cancer risk in selenium
deficiency [42]. Therefore, a research agenda to investigate the synergistic operation of such
substances in cancer treatment is required.
3. Cancer and oxidation
Cancer is a generic term for a large group of diseases that can affect any part of the body and
it can exist in many different forms and types, some of which are brought on by the destructive
choices people make while others are less predictable and are not the result of destructive
decisions. It can be broadly grouped into different types (Carcinomas, Sarcomas, Lymphomas
and Leukaemia’s), depending on which tissues they come from [43, 44]. Cancer develops when
cells multiply in the presence of oxidation and other damage. According to micro-evolutionary
models, cells become damaged and change their behaviour, growing uncontrollably, and act
like the single-celled organisms from which they originally evolved. The cancer cells’ indi‐
vidualism overwhelms the cooperative control processes that are essential to a complex
multicellular organism [45, 46]. As cancers become malignant, they exhibit incredible genetic
diversity. Whereas a benign tumour is like a colony of similar abnormal cells, a malignant
tumour is a whole ecosystem. At this late stage, some (but not all) antioxidants can indeed
promote cancer cell growth. Thousands of different cell types coexist: cooperating, competing,
and struggling to survive. A consequence of the anaerobic conditions that prevail during the
early development of a malignancy is that cancer cells differ from healthy cells, in that they
have been selected for the way they generate energy (i.e. anaerobically, using glucose) [47, 48].
The sulfhydryl group is the most sensitive to the oxidizing effects of ROS among the amino
acid side chains in protein; it is often involved in the intracellular transduction machinery of
redox signals in response to physiological and oxidative stimuli. In fact, a variety of biological
functions, not directly related to peroxidase activity, have also been reported for the Prx family
[49]. Oxidative damage in DNA can cause cancer. Several antioxidant enzymes such as
superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutathione S-
transferase etc. protect DNA from oxidative stress. It has been proposed that polymorphisms
in these enzymes are associated with DNA damage and subsequently the individual's risk of
cancer susceptibility [50].
Nutrition and physical activity and major lifestyle changes can reduce the risk of cancer [51,
52]. Antioxidants are becoming an increasingly common choice as a hopeful cancer prevention
agent. Importantly, antioxidants limit oxidative damage and thus inhibit early benign cancer
growth, preventing cancer from developing. Selenium has received publicity over the past
decades based on some confusing and contradictory research about whether low-selenium
diets are implicated in cancer risk. To date, this is still a question without a clear answer.
However, selenium is required for the proper activity of a group of enzymes collectively called
glutathione peroxidase. Each of these enzymes helps to turn toxic hydrogen peroxide into
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harmless water. Of the eight known glutathione peroxidase enzymes, five of them require
selenium. It is a necessary component for appropriate function of the immune system, muscle
function, successful reproduction, and peak brain function. Also, selenium produces valuable
antioxidant enzymes. Deficiencies in selenium have been linked to decreased thyroid function,
cardiovascular disease, and cancers [24]. Research shows selenium, especially when used in
conjunction with vitamin C, vitamin E and beta-carotene, works to block chemical reactions
that create free radicals in the body (which can damage DNA and cause degenerative change
in cells, leading to cancer). Also research has demonstrated that selenium is also linked to
reduction in risk to some carcinomas [6, 7].
4. Pathophysiology of cancer and causes
Cancer is a disease of regulation of tissue growth. In this disease, the cells of the body display
uncontrolled growth, invasion that intrudes and destroys adjacent tissues and spreads to other
body locations. In order for a normal cell to transform into a cancer cell, genes which regulate
cell growth and differentiation must be altered and DNA repair genes are altered and turned
off [53, 54]. The pathophysiology of cancer is a complicated issue. Genes that are influenced
in the pathogenesis of cancer are proteins that are involved in a variety of processes including
cell growth and differentiation, cell cycle processes, and angiogenesis, which is the formation
of new blood vessels [55]. These proteins also play a role in tumour progression, immune
regulation, and apoptosis. Since the cells involved are complex and have such a broad range
of functions, the pathophysiology of cancer has been hard to determine precisely.
Understanding what causes cancer is a complex process. Cancer has been linked to many
factors, such as environmental exposures, lifestyle practices, medical interventions, genetic
traits, viruses, familial susceptibility, and aging. Cancer is most probably the result of inter‐
actions between repeated carcinogenic exposures and an individual's susceptibility status [56].
Environmental exposures and lifestyle practices have been determined to be the major risk
factors in the development of cancer [57, 58]. The major lifestyle factors that contribute to cancer
include smoking, alcohol, diet, medical practices, and ultraviolet exposures.
Genes  that  are  influenced  in  the  pathogenesis  of  lung  cancer  are  proteins  that  are  in‐
volved  in  a  variety  of  processes  including  cell  growth  and  differentiation,  cell  cycle
processes, and angiogenesis, which is the formation of new blood vessels. The proteins also
play a role in tumour progression, immune regulation, and apoptosis [59,  60].  Since the
cells involved are complex and have such a broad range of functions, the pathophysiolo‐
gy of lung cancer has been hard to determine precisely. A healthy cell becomes a cancer
cell  by  undergoing  the  following  processes  in  which  proto-oncogenes  are  changed  to
oncogenes. Proto-oncogenes are genes that are coded to maintain normal cell growth. In
cases of a developing cancer, oncogene takes its place. Oncogene is a gene that makes cells
grow  and  divide  rapidly  [61].  Pharmaceutical  companies  are  continuing  to  develop
approaches for targeting oncogene activity in the ongoing war on cancer [61]. Pathology of
cancers and other complex disorders have undergone a big change after development of
Pharmacology and Nutritional Intervention in the Treatment of Disease298
technologies  like  immunohistochemistry,  flow  cytometry,  and  molecular  biologic  ap‐
proaches  to  cancer  diagnosis.  Cancer  is  not  a  singular,  specific  disease  but  a  group  of
variable tissue responses that result in uncontrolled cell growth [56].
5. Selenium mechanism
The biochemistry of selenium differs from other dietary minerals and trace elements. Selenium
is not a structural component nor a metal coordination complex and the biosynthesis of
selenocysteine is regulated by four genes and begins with the aminoacylation of the amino
acid serine by the enzyme serine synthetase to produce Ser-tRNASec [62, 63]. However,
selenocysteine is the active site in which, at physiological pH, selenium is fully ionized and is
a very efficient redox catalyst [64]. Selenium exists in elemental, organic, and inorganic forms,
with four important oxidation states: selenide (Se 2−), elemental (Se0) selenite (Se+4), and
selenate (Se+6) [62, 65]. Selenium compounds inhibit signaling enzymes such as protein kinase
C (PKC) [66] that play crucial roles in tumor promotion. The selenium-containing nutrient,
selenomethionine has been shown to regulate the tumor suppresser p53 by the redox factor
refl-dependent redox mechanism. Studies continue to support evidence that one important
pathway is that many selenium-containing nutrients can be converted in the body to methyl‐
selenol. Methylselenol has been shown to block expansion of pre-malignant cells forming into
fully developed cancers [67]. Several pathways have been proposed that could explain how
selenium-containing compounds could block mutated cells from progressing to cancer.
Methylseleninic acid has been shown to inhibit NF-kappa B and regulate I kappa B in prostate
cancer cells [68]. Selenium compounds inhibit signaling enzymes such as protein kinase C
(PKC) [66] that play crucial roles in tumor promotion. A representative of the hydrogen
selenide metabolic pool has been found to protect liver cells against damage to DNA. The
cellular redox-milieu involves several metabolic, antioxidative and regulatory aspects that are
maintained and regulated largely by two enzyme-based systems: the glutathione and thiore‐
doxin systems [69] The thioredoxin and glutathione systems constitute a balanced redox
network. The thioredoxin system may influence virtually all phases of tumorgenesis via its
involvement in transcription and translation [69].
There are several possible mechanisms for the protective effect of selenium. Selenium activates
an enzyme in the body called glutathione peroxidase that protects against the formation of
free radicals—those loose molecular cannons that can damage DNA. There appear to be at
least two distinct families of selenium-containing enzymes [70, 71]. The first includes gluta‐
thione peroxidases Bermano et al [72] and thioredoxin reductase [73], which are involved in
controlling tissue concentrations of highly reactive oxygen-containing metabolites. These
metabolites are essential at low concentrations for maintaining cell-mediated immunity
against infections but highly toxic if produced in excess.
The role of selenium in the cytosolic enzyme glutathione peroxidase (GPx) was first illustrated
[74, 75]. During stress, infection, or tissue injury, selenoenzymes may protect against the
damaging effects of hydrogen peroxide or oxygen-rich free radicals. This family of enzymes
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catalyses the destruction of hydrogen peroxide or lipid hydroperoxides according to the
following general reactions:
Selenium-containing glutathione peroxidases (GPx) constitute a family of anti-oxidative
enzymes that are capable of reducing organic and inorganic hydroperoxides to the corre‐
sponding hydroxy compounds utilizing glutathione or other hydrogen donors as reducing
equivalents
2 2 2
2
H O + 2GSH 2H O + GSSG
ROOH + 2GSH ROH + H O + GSSG
× × × × × × × × × × × × × ×
× × × × × × × × × × × × (1)
Where GSH is glutathione and GSSG is its oxidized form. At least four forms of GPx exist; they
differ both in their tissue distribution and in their sensitivity to selenium depletion [72]. The
GPx enzymes of liver and blood plasma fall in activity rapidly at early stages of selenium
deficiency. In contrast, a form of GPx associated specifically with phospholipid-rich tissue
membranes is preserved against selenium deficiency and is believed to have broader metabolic
roles (e.g., in prostaglandin synthesis) [76]. In concert with vitamin E, selenium is also involved
in the protection of cell membranes against oxidative damage. The selenoenzyme thioredoxin
reductase is involved in disposal of the products of oxidative metabolism [77]. It contains two
selenocysteine groups per molecule and is a major component of a redox system with a
multiplicity of functions, among which is the capacity to degrade locally excessive and
potentially toxic concentrations of peroxide and hydroperoxides likely to induce cell death
and tissue atrophy [76].
There is strong evidence that oxidative free radicals have a role in the development of
degenerative diseases including CHD [78]. Oxidative free radicals increase the peroxidation
of low density lipoprotein thereby increasing its uptake by macrophages with increased foam
cell formation and atherosclerosis [79], though other mechanisms may exist. Anti-oxidants in
the diet include vitamin A (carotenoids, which are metabolised to retinol), vitamin C (ascor‐
bate), vitamin E (tocopherol), and selenium, which is an integral part of the antioxidant enzyme
glutathione peroxidase:
6. Selenium function
Despite an evident progress in cancer diagnosis and treatment, there is a constant need of a
drug which could arrest the premalignant process, thus reducing the risk of cancer. However,
the role of selenium (Se) as an antioxidant and anticancer agent is well documented [80]. In
addition, it has been proven that an adequate concentration of selenium can restore the
sensitivity to chemotherapeutic agents of cytostatic-resistant malignant cells [81]. Selenium
can exist with oxidation state-2,+2,+4,+6, and Se (II) is the dominant form in organoselenium
chemistry [82]. The highest activity as a free radical scavenger and anticancer agent is assigned
to selenium compounds containing selenium at the+4 oxidation level [83]. Other essential role
of selenium in human and animal nutrition is well established. In humans, it has been
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demonstrated that an endemic cardiomyopathy (Keshan disease) prevalent in certain areas of
China is correlated with selenium deficiency [84, 85]. Selenium is often thought to be a dietary
antioxidant, but the antioxidant effects of selenium are most likely due to the antioxidant
activity of proteins that have this element as an essential component (i.e., selenium-containing
proteins), and not to selenium itself [86]. The damage to cells caused by free radicals, especially
the damage to DNA, may play a role in the development of cancer and other health conditions
[40]. Many observational studies, including case–control studies and cohort studies, have been
conducted to investigate whether the use of dietary antioxidant supplements is associated with
reduced risks of cancer in humans. Overall, these studies have yielded mixed results [87].
Healthy Chinese men and women at increased risk of developing esophageal cancer and
gastric cancer were randomly assigned to take a combination of 15 milligrams (mg) beta-
carotene, 30 mg α-tocopherol, and 50 micrograms (μg) selenium daily for 5 years or to take no
antioxidant supplements. The initial results of the trial showed that people who took antiox‐
idant supplements had a lower risk of death from gastric cancer but not from oesophageal
cancer. However, their risks of developing gastric cancer and/or esophageal cancer were not
affected by antioxidant supplementation [88].
As an essential trace element in humans [89], it’s only established function is its presence in
the enzyme glutathione peroxidase [90]. Using GSH2 as the reducing equivalent, this enzyme
plays a significant role in detoxification of peroxides induced by oxygen radicals. As such it
may be important in the toxicity of anticancer treatments that generate such reactive molecules
[91]. In addition, epidemiological and experimental data suggest an anti-carcinogenic activity
by selenium [92]. Considerable epidemiological data suggests that cancer mortality is inversely
correlated with selenium consumption. Chemoprotective effect of diphenylmethyl selenocya‐
nate against cyclophosphamide (CP) induced cellular toxicity and antitumor efficacy was
evaluated in mice bearing Ehrlich ascites carcinoma [93], their results indicate that diphenyl‐
methyl selenocyanate has the potential to reduce the cellular toxicity of CP at the same time
improving its antitumor efficacy. Supplementation of a torula yeast-based diet with 2.5 or 5.0
ppm Selenium as Na2SeO3 also significantly increased the survival time of EAT-bearing mice
[94]. Their data show that the form and mode of administration of selenium influence the
antitumorigenic properties of this trace element. In addition, they suggested that some
intermediate in the normal pathway for selenium detoxification is probably responsible for
this trace element's antitumorigenic properties [94]. The ability of selenium to inhibit or
prevent the growth of Ehrlich as cites tumour cells was highly dependent upon the form and
quantity of selenium administered [95]. The only significant alteration that has been observed
in mice treated with quantities of selenium at dosages of 4μg 3 times weekly was a slight
reduction in intestinal weights. The reduction in intestinal weights was not attributable to a
reduction in the intestinal macro constituents, suggesting that selenium may have altered
rapidly dividing cells [95]. In fact selenocystine was used in the treatment of human leukaemia
in 1956 with some short term success [96, 97]. The mechanism of its effect was thought to be
competitive deprivation of cystine, but this was not proven. Others have shown that selenium
compounds can cause chromosome breaks and inhibit critical DNA synthetic enzymes [98].
Specific incorporation of selenium into RNA molecules has been observed in several bacterial
species. Since in a number of instances modified bases in RNAs have been shown to be involved
in regulatory functions of the RNAs, the selenium-modified bases may have similar roles.
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Furthermore, some RNA viruses, as well as leader mRNAs contain RNA-like segments that
may interact with specific enzymes and, thus, play regulatory roles [99]. Hence, it is reasonable
to assume that detailed information concerning selenium-modified RNAs may contribute to
the understanding of the biological roles of selenium [100]. Near toxic levels of selenium have
been reported to produce tumours in rats but other studies indicated that these concentrations
of selenium created chronic toxic hepatitis that resembled hyperplasia.
In mammals glutathione peroxidase is the only selenium-dependent enzyme so far identified,
but it seems unlikely that the complicated biological effects of selenium in man and animals
are attributable solely to variations in the level of this enzyme. In fact, at least two other seleno
proteins of unknown catalytic activity have been detected in animals. Investigations in a
variety of animal systems have suggested that there is a significant interaction of selenium
with glutathione independent of the enzyme glutathione peroxidase [101]. White muscle
disease (WMD), a degenerative muscle disease, found in domestic animals [102, 103]. It is
caused by a deficiency of selenium and/or vitamin E. Selenium and vitamin E deficiencies can
produce symptoms of ill thrift and reproductive losses: lower conception rates, fetal reabsorp‐
tion, dystocia, retained placenta, reduced milk production, and reduced semen quality, poor
rate of growth or ill thrift in young lambs, low wool yields and have increased incidence of
periodontal disease [102, 103]. Selenium appears to be a key nutrient in counteracting the
development of virulence and inhibition of HIV progression to AIDS. It is required for sperm
motility and may reduce the risk of miscarriage. Selenium deficiency has been linked to
adverse mood states and some findings suggest that selenium deficiency may be a risk factor
in cardiovascular diseases [104]. Studies continue to confirm that people with higher levels of
selenium in their blood have lower rates of prostate and lung cancers [105].
Selenium is synergistic with vitamin E; they serve related metabolic functions and share in
common the role of endogenous antioxidants [106]. Vitamin E has a free radical Scavenger,
and Se as a component of the peroxide reducing enzyme, glutathione peroxidase. Vitamin E
restricts the formation of peroxides by neutralizing free radicals, an integral component of
glutathione peroxidase, an enzyme responsible for the removal of hydrogen peroxide and
organic hydroperoxides [107].
Selenium and vitamin C; CH3SeH is thought to be a critical metabolite in Se chemoprevention
[108, 109]. The family of selenoenzymes called thioredoxin reductases catalyze the NADPH-
dependent reduction of oxidized thioredoxin, hyperoxides, dehydroascorbate, ubiquinol and
other substrates [110].The action of thioredoxin reductases in recycling dehydroascorbate to
ascorbate (vitamin C) now explain the synergistic action of selenium and vitamin C [111]. The
thioredoxin system is also capable of regenerating proteins inactivated by ROS. Daily supple‐
mentation with vitamin C (120 mg), vitamin E (30 mg), beta-carotene (6 mg), and the minerals
selenium (100 μg) and zinc (20 mg) for a median of 7.5 years had no effect on the incidence of
cancer or cardiovascular disease or on all-cause mortality [112]. Antioxidant and mineral
supplementation was associated with lower total cancer incidence and all-cause mortality
among men but not among women, and with an increase in skin cancer incidence, including
melanoma, among women but not among men [113].
Selenium and Silver; Selenium serves as a major protective factor in precipitating the silver in
a highly insoluble and hence inert form of silver selenide. Although some of this may be taken
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up in lysosomes in macrophages, the deposits are essentially long lived or permanent [114].
A lack of positive effect of Se supplementation on the prostate cancer incidence was observed
in this study.
7. Conclusion
Selenium as non-metals is an essential nutrient that acts as cofactor in enzyme oxidation–
reduction reactions. It maintains the specific configurations of proteins, is incorporated into
the structure of hormones, and plays a structural and catalytic role in gene expression and
transcriptional regulation. In the physiological dosage range, Se appears to function as an
antimutagenic agent, preventing the malignant transformation of normal cells and the
activation of oncogenes. These protective effects of Se seem to be primarily associated with its
presence in the glutathione peroxidases, which are known to protect DNA and other cellular
components from damage by oxygen radicals. Selenoenzymes are also known to play roles in
carcinogen metabolism, in the control of cell division, oxygen metabolism, detoxification
processes, apoptosis induction and the functioning of the immune system. Other modes of
action, either direct or indirect, may also be operative, such as the partial retransformation of
tumor cells and the inactivation of oncogenes.
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